

FOR *IN VITRO* DIAGNOSTIC USE ONLY FOR PRESCRIPTION USE ONLY

DPP[®] HIV-Syphilis

Single-Use Rapid Test for the Detection of Antibodies to HIV-1/2 and/or Treponema pallidum

Read this Product Insert completely before using the product. Conformance with the test procedure is necessary to ensure accurate results. Users of this test should follow the CDC Universal Precautions for prevention of transmission of Human Immunodeficiency Virus, Hepatitis B Virus, and other bloodborne pathogens.¹

STORAGE: Store at 2 to 25°C (36 to 77°F)

CLIA Complexity: Waived for Fingerstick Whole Blood

CLIA Complexity: Moderate for Venous Whole Blood and Plasma Specimens

Any modification by the laboratory to the DPP HIV-Syphilis or the FDA approved DPP HIV-Syphilis instructions will result in the test no longer meeting the requirements for waived category.

A CLIA Certificate of Waiver is required to perform the test in a waived setting. Additional CLIA waiver information is available at the Centers for Medicare and Medicaid website at www.cms.hhs.gov/CLIA or from your state health department.

NAME AND INTENDED USE

The DPP® HIV-Syphilis is a single-use rapid, qualitative, multiplex, immunoassay for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1/2), and/or *Treponema pallidum* bacteria (the causative agent of syphilis) in fingerstick whole blood, potassium-EDTA venous whole blood or potassium-EDTA plasma specimens. The test is intended to be used with the DPP Micro Reader. The test is intended for use by trained professionals in point of care and laboratory settings to aid in the diagnosis of HIV and syphilis infection.

This test is suitable for use in multi-test algorithms designed for the statistical validation of rapid HIV test results and when multiple rapid HIV tests are available.

The test is intended to be used as the first-tier assay in the reverse sequence syphilis screening algorithm to aid in the detection of infection with *T. pallidum*. A diagnosis of syphilis must be made in the context of treponemal and non-treponemal test results and in conjunction with clinical findings. This test is not intended for use as a confirmatory test in the reverse sequence syphilis screening algorithm.

The results of DPP HIV-Syphilis tests are read and interpreted only by DPP Micro Reader with dedicated software.

The test is not intended for use in screening blood, blood products, or human cells or tissue or cellular and tissue-based products (HCT/Ps) for HIV and Syphilis.

RESTRICTIONS

- Sale of DPP HIV-Syphilis is restricted to clinical laboratories that have an adequate quality assurance program including planned activities to provide adequate confidence that requirements for quality will be met; and
- Where there is assurance that operators will receive and use instructional materials;
- DPP HIV-Syphilis is approved for use only by an agent of a clinical laboratory;
- Test subjects must receive the SUBJECT INFORMATION NOTICE, prior to specimen collection and appropriate counseling when test results are provided.
- DPP HIV-Syphilis is not approved for use to screen donors of blood, plasma, cells, or tissue.

SUMMARY AND EXPLANATION

Discovered in 1983, the Human Immunodeficiency Virus is a retrovirus and identified as the etiologic agent for the Acquired Immunodeficiency Syndrome (AIDS), and AIDS related complex.² AIDS is characterized by changes in the population of T-cell lymphocytes that play a key role in the immune defense system. In the infected individual the virus causes a depletion of a subpopulation of T-cells, called T-helper cells, which leaves these patients susceptible to opportunistic infections and certain malignancies. The major routes of transmission are sexual contact, exposure to contaminated blood or blood products (including sharing of contaminated syringes and needles) and mother-to-newborn transmission.³⁻⁵ The HIV virus consists of a genomic RNA molecule protected by a capsid and an envelope. The HIV envelope is the major target for a humoral antibody response. The presence of the virus in patients causes the immune system to elicit the production of antibodies, which will develop between 23 to 90 days following exposure.⁶⁷ The detection of these antibodies can be used as a diagnostic tool. In a nonclinical or point of care setting for HIV testing, individuals are commonly screened with a rapid HIV and if are reactive, are linked to care or laboratory follow-up. As per CDC Guidelines, laboratory testing consists of an initial antibody/antigen assay which if reactive would be followed by a supplemental antibody assay that differentiates between HIV-1 and HIV-2 antibodies. A nonreactive or indeterminate result for both HIV-1 and HIV-2 antibodies on the supplemental assay would be followed by an HIV-1 Nucleic Acid Test (NAT) to rule out an acute HIV-1 infection.8.9

Syphilis is a sexually transmitted disease (STD) caused by the spirochete organism Treponema *pallidum*, and depending on the stage of the disease, manifestation of symptoms includes ulcers or chancres at the infection site (primary syphilis); skin rash, mucocutaneous lesions, and lymphadenopathy (secondary syphilis); and/or cardiac, aummatous lesions, tabes dorsalis, and general paresis (tertiary syphilis). Latent syphilis, which lacks the clinical manifestations of symptoms described is detected by serologic testing. At any stage, T. *pallidum* can infect the central nervous system and result in neurosyphilis which may manifest as cranial nerve dysfunction, meningitis, stroke, acute altered mental status and auditory or ophthalmic abnormalities.¹⁰ As T. pallidum cannot be cultured on artificial media, the diagnosis of syphilis depends on the correlation of clinical data with antibodies demonstrated by serological tests. Two types of antibody responses normally result: non-specific (nontreponemal/anti-cardiolipin)^{11,12} and specific (anti-treponemal). Non-treponemal antibodies are typically produced 3 to 6 weeks after exposure while anti-treponemal antibodies are typically produced 2 to 4 weeks after exposure.¹³ Treponemal antibodies typically remain detectable for life, even following successful treatment.¹⁴ Syphilis is diagnosed via serology testing using one of two algorithms, a traditional algorithm consisting of initial screening with a non-treponemal test followed by retesting a reactive specimen with a treponemal test, or a reverse sequence screening algorithm where a screening is initiated using a treponemal test and confirmed with a non-treponemal test. In the reverse sequence screening algorithm, if the non-treponemal test is nonreactive, then a different treponemal test is performed to confirm the results of the initial test. If the second treponemal test is positive, treatment should be dependent on the individual's history of treatment for syphilis.^{10,15}

HIV and syphilis represent serious public health concerns not only in isolation from another but also due to the potential for coinfection. Syphilis facilitates both HIV transmission and HIV acquisition, reflecting the complex interplay between the two diseases. Chancres cause epithelial and mucosal breaches, facilitating the transmission of HIV virions.¹⁶

BIOLOGICAL PRINCIPLES OF THE TEST

DPP HIV-Syphilis employs Chembio's patented DPP (Dual Path Platform) technology and consists of a sample path and a reagent path, which intersect in the antibody detection TEST (1) (2) and CONTROL (C) areas in the readout window of the test cassette. To initiate the test, a specimen is mixed with pre-measured buffer in a DPP SampleTainer® Bottle for 10 seconds, and is applied to the SAMPLE+BUFFER Well #1 of the DPP test device. The sample migrates along the sample path membrane and is delivered to the TEST (1) (2) area of the reagent strip, where specific HIV antigens, a syphilis recombinant antigen and Protein A are immobilized. Antibodies to HIV and/or *Treponema pallidum*

(i.e. treponemal antibodies), if present in the sample, bind instantly to the immobilized HIV and/or syphilis antigens in the TEST (1) (2) area, while non-specific IgG binds to the Protein A in the CONTROL (C) area. Successful sample application is indicated by the dissolution of soluble dve lines in the TEST and CONTROL areas. Five minutes after adding the sample, buffer is added to the BUFFER Well #2. The buffer hydrates the dried antibody-binding colored conjugate, which migrates to the TEST area. The test results are interpreted using the DPP Micro Reader between 10 and 25 minutes after Running Buffer is added to BUFFER Well #2. The DPP Micro Reader is a reflectance reader for use with DPP HIV-Syphilis. The DPP Micro Reader is a portable, battery-powered instrument that uses assay-specific algorithms to analyze the test and control line reflectance to determine the presence or absence of the antibodies to HIV and/or Treponema pallidum in the sample. The reader verifies the presence of the control line and measures color intensity at each of the test line positions; it interprets the results using an algorithm including assay-specific cut-off values, and reports a positive, negative, or invalid result. The results are displayed through a 14-segment liquid crystal display (LCD) on the top of the instrument. The DPP Micro Reader has been developed to minimize human interpretation errors, therefore the results cannot be visually interpreted by the operator. The DPP Micro Reader is maintenance-free, not configurable by the user and is operated by a single, multi-function button.

MATERIALS PROVIDED

Each kit contains the items to perform 20 tests: (Catalog # 65-9502-0)

- 20 Individually Pouched DPP HIV-Syphilis Test Devices, each containing:
 - 1 DPP HIV-Syphilis Test Device
 - 1 Desiccant Pouch
- 20 Disposable 10 μL Sample Loops with Break Point BLUE
- 20 SampleTainer® Bottle BLACK Cap
 - 1 mL, a phosphate buffer containing sodium chloride, EDTA, Tween 20, Avidin, and chicken serum, antimicrobials and sodium azide as preservative.
- 1 DPP Running Buffer GREEN Cap
 - 6 mL, a phosphate buffer containing sodium chloride, EDTA, Tween 20, Avidin, and chicken serum, urea, antimicrobials and sodium azide as preservative.
- 20 Subject Information Notice Handouts
- 1 Product Insert for DPP HIV-Syphilis

ACCESSORIES AVAILABLE AND REQUIRED

DPP HIV-Syphilis Rapid Test Control Pack (Catalog # 60-9555-0) Each package contains:

- HIV-1/Syphilis Reactive Control
 - One Vial containing 0.5 mL of heat inactivated human plasma positive for antibodies to HIV-1 and *T. pallidum*, diluted in normal human plasma. Negative for Hepatitis B surface antigen, Hepatitis C antibody and HTLV I/II antibodies.
- HIV-2 Reactive Control
 - One Vial containing 0.5 mL of heat inactivated human plasma positive for antibodies to HIV-2, diluted in normal human plasma. Negative for Hepatitis B surface antigen, Hepatitis C antibody, HTLV I/II antibodies and treponemal antibodies.
- Non-reactive Control
 - One Vial containing 0.5 mL of normal human plasma negative for antibodies to HIV-1, HIV-2 and *T. pallidum*. Negative for Hepatitis B surface antigen, Hepatitis C antibody and HTLV I/II antibodies.
- 1 Product Insert for the DPP HIV-Syphilis Rapid Test Control Pack

ACCESSORIES AVAILABLE AND REQUIRED (continued)

DPP Micro Reader (Catalog # 70-1056-0) Each kit contains:

- 1 DPP Micro Reader configured for use with DPP HIV-Syphilis
 3 Lithium-ion, type CR2032 (3 V/230 mAh), coin cell batteries (installed)
- 1 DPP Test Device Holder
- 1 USB Wall Power Adapter (5v / 1000 mA) with cable
- 1 Microfiber cloth
- 1 User Manual

MATERIALS REQUIRED BUT NOT PROVIDED

- Clock, watch, or other timing device
- Disposable gloves
- Antiseptic wipes
- Biohazard disposal container
- For fingerstick whole blood specimens:
 - Sterile safety lancet
 - Sterile gauze
- For venous whole blood, plasma:
 - Collection devices
 - Pipettor capable of delivering 10µL of sample

WARNINGS

For IN VITRO Diagnostic Use

- 1. Read the Product Insert completely before using this assay. Conformance with the test procedure is necessary to ensure accurate results.
- 2. Users of this test should follow the CDC Universal Precautions for prevention of transmission of Human Immunodeficiency Virus, Hepatitis B Virus, and other bloodborne pathogens.¹
- 3. Use of this test kit with sample types other than those specifically approved for use with this device may result in inaccurate test results.
- 4. Ensure that the test components are at room temperature before performing the test. This test should be performed at 18 to 25°C (64 to 77°F).
- 5. The results of DPP HIV-Syphilis tests are read and interpreted only by DPP Micro Reader with dedicated software. Results should not be readmanually.
- 6. This test has not been evaluated for newborn screening, cord blood specimens, or individuals less than 2 years of age.
- 7. Individuals infected with HIV-1 and/or HIV-2 who are receiving antiretroviral therapy (ART), PrEP (Pre-exposure prophylaxis) or PEP (Post-exposure prophylaxis) may produce false negative results.

PRECAUTIONS SAFETY PRECAUTIONS

- 1. Handle the samples, materials contacting samples, and kit controls as if capable of transmitting infection.
- Do not eat, drink or smoke in the area where samples and kit reagents are handled. Avoid any contact between hands, eyes or mouth during sample collection & testing.
- 3. Wearprotective clothing such as laboratory coats, disposable gloves and eye protection when handling patient samples.
- 4. Dispose of all samples and materials used in the test procedure in a biohazard waste container. Lancets should be placed in a puncture-resistant container prior to disposal. The recommended method of disposal of biohazard waste is autoclaving for a minimum of 1 hour at 121°C. Disposable materials may be incinerated. Liquid wastes may be mixed with appropriate chemical disinfectants. A freshly prepared solution of 10% bleach (0.5% solution of sodium hypochlorite) is recommended. Allow 60 minutes for effective decontamination. NOTE: Do not autoclave solutions that contain bleach.
- 5. Use 10% bleach or other appropriate disinfectants to wipe all spills. The bleach solution should be made fresh each day.
- 6. For additional information on biosafety, refer to "Universal Precautions for prevention of transmission of Human Immunodeficiency Virus, Hepatitis B Virus, and other bloodborne pathogens"¹ and "Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposure to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis."¹⁷ and "Update U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis".¹⁸

HANDLING PRECAUTIONS

- 1. If Desiccant Packet is missing, DO NOT USE. Discard test device and use a new test device.
- 2. Do not use any test device if the pouch has been perforated.
- 3. Each test device is for single use only.
- 4. Do not use the test beyond the expiration date printed on the pouch. Always check expiration date prior to testing.
- 5. Do not mix reagents from different lot numbers of kits.
- 6. Adequate lighting is required to read the test results with the DPP Micro Reader.
- 7. Do not open the sealed foil pouch until just prior to use.
- 8. Ensure finger is completely dry before performing fingerstick.

STORAGE AND STABILITY

DPP HIV-Syphilis Test Devices should be stored in unopened pouches at 2 to 25°C (36 to 77°F). Do not freeze. Do not open pouch until you are ready to perform a test. When stored as indicated, test devices are stable until the expiration date marked on the pouch. Both Running Buffer and DPP SampleTainer Bottles should be stored at 2 to 25°C (36 to 77°F) in their original containers.

SPECIMEN COLLECTION

Prior to specimen collection, provide test subjects with SUBJECT INFORMATION NOTICE and pre-test counseling according to CDC Guidelines for Rapid HIV Testing.¹⁹

DPP HIV-Syphilis can be performed on fingerstick whole blood, potassium-EDTA venous whole blood or potassium-EDTA plasma samples.

FINGERSTICK WHOLE BLOOD COLLECTION

Before collecting the sample, write the patient sample ID on the DPP SampleTainerBottle with the BLACK CAP (Figure 1). Remove (unscrew) the WHITE CAP keeping the BLACK CAP screwed onto the white part of the cap (Figure 2).

 Figure 1:
 Figure 2:

 DPP SampleTainer Bottle
 DPP SampleTainer Bottle

 Image: Figure 2:
 Removing WHITE CAP from DPP SampleTainer Bottle

 Image: Figure 2:
 DPP SampleTainer Bottle

 Image: Figure 2:

Perform fingerstick collection as per normal laboratory procedures.

Using an alcohol wipe, clean the finger of the person being tested.

Note: Using the middle or ring finger of the non-dominant hand is recommended.

Allow the finger to dry thoroughly or wipe dry with a sterile gauze pad as alcohol will affect the test.

Using a sterile lancet, capable of producing a 50µl bleed, puncture the skin just off the center of the finger pad (see Figure 3 below).

Apply gentle pressure beside the point of the puncture. Wipe away the first drop of blood with a sterile gauze pad. Allow a second drop of blood to form. If blood flow is inadequate, the subject's finger may be gently massaged to produce a droplet of sufficient volume. Avoid squeezing the fingertip to accelerate bleeding as this may dilute the blood with excess tissue fluid.



Hold the loop in a horizontal position and bring the loop down on to the blood drop from above to collect the sample (Figure 4).

Important: Wait until a large enough drop has formed before collecting fingerstick sample. Do not attempt to collect the sample before the blood drop is large enough to fill the loop.

Figure 4: Fingerstick Collection



Ensure loop is properly filled with sample (as depicted in Figure 5 below) before proceeding to add the sample to the DPP SampleTainer Bottle.

If necessary, safely discard the sample loop (in biohazard waste) and repeat the sample collection process.



Insert the filled Sample Loop into the DPP SampleTainer Bottle with the BLACK CAP, such that the loop is touching the bottom. Snap and twist the shaft at the BREAK-NOTCH to dislodge the Sample Loop into the DPP SampleTainer Bottle, as shown in Figure 6. Replace the BLACK/WHITE CAP assembly onto the DPP SampleTainer Bottle and gently shake for 10 seconds (**Note:** Make sure that the cap is tightly screwed on).

Test immediately, following Test Procedure instructions.



POTASSIUM-EDTA VENOUS WHOLE BLOOD

Draw blood following laboratory procedure for obtaining potassium-EDTA venous blood. Collect sample in a tube containing potassium-EDTA. Be sure the tube of blood is well mixed before sampling.

If using a laboratory pipette, with draw 10μ L of the blood from the tube. Pipette the sample into the DPP SampleTainer Bottle with the BLACK CAP.

If using the Sample Loop, dip the Sample Loop into the blood tube and allowit to fill. Insert the filled Sample Loop into the DPP SampleTainer Bottle with the BLACK CAP, such that the loop is touching the bottom. Snap and twist the shaft at the BREAK-NOTCH to dislodge the loop into the DPP SampleTainer Bottle, as shown in Figure 6.

Replace the BLACK/WHITE CAP assembly onto the DPP SampleTainer Bottle and shake for 10 seconds. Test immediately, following Test Procedure instructions.

If tested the same day, potassium-EDTA venous whole blood may be kept at room temperature. Potassium-EDTA venous whole blood may be stored for up to 3 days between 2 and 8°C (36 to 46°F) before testing.

DO NOT FREEZE WHOLE BLOOD! Allow refrigerated sample to reach room temperature and mix gently before testing.

POTASSIUM-EDTA PLASMA

Draw blood following laboratory procedure for obtaining potassium-EDTA plasma specimens. Collect plasma specimens in tubes containing potassium-EDTA. Collect specimen in a clean container following standard laboratory procedures. Samples collected into potassium-EDTA tubes should be processed according to the manufacturer's direction for centrifugation and removal of the plasma from red blood cells.

If using a laboratory pipette, withdraw 10 μ L of potassium-EDTA plasma. Pipette the sample into the DPP SampleTainer Bottle with the BLACK CAP.

If using the Sample Loop, dip the Sample Loop into the tube and allow it to fill. Insert the filled Sample Loop into the DPP SampleTainer Bottle with the BLACK CAP, such that the loop is touching the bottom. Snap and twist the shaft at the BREAK-NOTCH to dislodge the loop into the DPP SampleTainer Bottle, as shown in Figure 6.

Replace the BLACK/WHITE CAP assembly onto the DPP SampleTainer Bottle and shake for 10 seconds. Test immediately, following Test Procedure instructions.

Potassium-EDTA plasma specimens may be tested immediately after collection. If specimens are not tested immediately, refrigerate them at 2 to 8°C (36 to 46°F) following collection. These specimens should be tested within 3 days of collection. If specimens are not tested within 3 days of collection, potassium-EDTA plasma specimens should be frozen at -20°C (-4°F) or colder.

SPECIMEN SHIPPING

If specimens are to be shipped, they should be packed in compliance with regulations covering the transportation of etiologic agents. Potassium-EDTA venous whole blood and potassium-EDTA plasma specimens should be shipped refrigerated with cold packs or wet ice.

TEST PROCEDURE

All components for DPP HIV-Syphilis are ready to use as supplied. Follow directions as indicated. If the sample and/or kit components have been refrigerated, remove them from the refrigerator and allow them to come to a temperature of 18 to 25° C (64 to 77° F) prior to testing.



Test Results can be read using the DPP Micro Reader between 10 and 25 minutes after the addition of the Running Buffer to BUFFER Well 2 using the DPP Micro Reader.

DO NOT ATTEMPT TO INTERPRET THE RESULTS VISUALLY. ALWAYS USE THE DPP Micro Reader TO OBTAIN THE RESULTS.

NOTE: Discard the used Sample Loop, Test Device, and any other test materials into a biohazard waste container.

5. Using the DPP Micro Reader

Check to make sure that the window at the bottom of the reader is clean of finger marks and dust or lint before using the reader.

The Reader and Test Device Holder assembly must be on top of the Test Device when reading the device for results to be valid. Place the DPP Test Device Holder on a flat surface. Match the Reader with the DPP Test Device Holder by inserting the base of the Reader so that the "slanted edge" meets the corresponding "slanted corner" in the Test Device Holder socket.

5A. Connect the DPP Micro Reader to the supplied Test Device Holder as shown below. The DPP Micro Reader is secure in the DPP Test Device Holder once you feel it snap into place and a "clicking" sound is heard.







Test Device Holder



DPP Micro Reader with Test Device Holder and Test Device

- 5B. At the time indicated for reading the test results, place the DPP Micro Reader and Test Device Holder on top of the Test Device and press the button. The DPP Micro Reader will go through the start-up process:
 - Self-check shows all display segments
 - Number of remaining tests available
 - Display "RDY": Ready to read
- 5C. Press the button again; the DPP Micro Reader will show "*RUN"*.





After a few seconds, results for HIV and for treponemal antibodies will be displayed one after the other. (Please see section on the next page: INTERPRETATION OF TEST RESULTS).

NOTE: Results will be displayed for approximately 50 seconds before the DPP Micro Reader shuts off.

NEXT TEST

To read another test while the previous results are still scrolling, press the button. The DPP Micro Reader goes to the "RDY'' mode. Insert the next Test Device into the Test Device Holder. At the time indicated to read the result, follow instructions starting with Step 5C.

INTERPRETATION OF TEST RESULTS

DO NOT ATTEMPT TO INTERPRET RESULTS VISUALLY.

NON-REACTIVE for HIV-1 or HIV-2 Antibodies

NON-REACTIVE for Treponemal Antibodies

REACTIVE for HIV-1 or HIV-2 Antibodies

NON-REACTIVE for Treponemal Antibodies

NON-REACTIVE for HIV-1 or HIV-2 Antibodies

REACTIVE for Treponemal Antibodies

REACTIVE for HIV-1 or HIV-2 Antibodies

REACTIVE for Treponemal Antibodies

INVALID RESULT

An invalid result cannot be interpreted. It is recommended that the invalid test be repeated with a new device. Call Customer Support if repeat run result is invalid.

HIV RESULTS INTERPRETATION

A nonreactive test result means that HIV-1 and HIV-2 antibodies were not detected in the specimen. The test result is interpreted as NEGATIVE for HIV-1 and HIV-2 antibodies.

A reactive test result means that HIV-1 and/or HIV-2 antibodies have been detected in the specimen. The test result is interpreted as Preliminary POSITIVE for HIV-1 and/or HIV-2 antibodies. Follow CDC guidelines to inform the test subject of the Test Result and its interpretation.¹⁹

THE FOLLOWING WILL SCROLL ACROSS READER DISPLAY











SYPHILIS RESULTS INTERPRETATION

Test results are intended to aid in diagnosis only. As with all serological tests for syphilis, results should always be interpreted in conjunction with additional treponemal or non-treponemal serologic test results (as appropriate), the patient's clinical symptoms, medical history, and other clinical and/or laboratory findings. Diagnostic considerations should be based on treponemal and non-treponemal testing according to the CDC guidelines.¹⁰

Reactive test result for treponemal antibodies may indicate recent, past, or successfully treated syphilis. A reactive treponemal test result on DPP HIV-Syphilis is not diagnostic of syphilis without additional non-treponemal serologic testing and a full clinical evaluation.

A nonreactive syphilis result on DPP HIV-Syphilis does not exclude incubating or early primary syphilis.

For problems or questions, please read the DPP Micro Reader User Manual, or contact Chembio Diagnostic Systems Customer Service at 1-844-CHEMBIO (1-844-243-6246).

LIMITATIONS OF THE PROCEDURE

- DPP HIV-Syphilis must ONLY be used with capillary (fingerstick) or potassium-EDTA venous whole blood, or potassium-EDTA plasma. Using other types of samples or testing of venipuncture whole blood or plasma samples collected using a tube containing an anticoagulant other than potassium-EDTA may not yield accurate results.
- DPP HIV-Syphilis must be used in accordance with the instructions in this product insert to obtain accurate results.
- Reading test results using the DPP Micro Reader earlier than 10 minutes or later than 25 minutes after the addition of DPP Running Buffer to BUFFER Well 2 may yield erroneous results.
- An HIV REACTIVE result using DPP HIV-Syphilis suggests the presence of antibodies to HIV-1 and/or HIV-2 in the sample and the REACTIVE test result is interpreted as Preliminary Positive for HIV-1 and/or HIV-2 antibodies. DPP HIV-Syphilis is intended as an aid in the diagnosis of infection with HIV-1/2. AIDS-related conditions are clinical syndromes, and their diagnosis can only be established using clinical and/or serological methods.
- A NON-REACTIVE HIV result does not preclude the possibility of exposure to HIV or infection with HIV. An antibody response to a recent exposure may take several months to reach detectable levels.
- A person who has antibodies to HIV-1 or HIV-2 is presumed to be infected with the virus, except that a person who has participated in an HIV vaccine study may develop antibodies to the vaccine and may or may not be infected with HIV.
- An individual infected with HIV-1 and/or HIV-2 who is receiving antiretroviral therapy (ART), PrEP (pre-exposure prophylaxis), or PEP (post-exposure prophylaxis) may produce a false negative result.
- This assay has not been evaluated for newborn screening, cord blood specimens, or for screening blood, blood products, tissue or organ donors for HIV and syphilis.
- Specimens from individuals with Systematic Lupus Erythematosus (SLE), anti-Cytomegalovirus (CMV) IgM antibodies, or anti-Double Stranded DNA (dsDNA) antibodies may cross-react with the treponemal test line, generating false reactive results for treponemal antibodies.

QUALITY CONTROL Built-in Control Feature

The control line serves as a built-in internal control and gives confirmation of sample addition and propertest performance. The DPP Micro Reader verifies the presence of the control line and measures colorintensity at each of the test line positions; it interprets the results using an algorithm including assay-specific cut-off values, and reports a reactive, nonreactive or invalid result after approximately 3 seconds. (Please see: INTERPRETATION OF TEST RESULTS).

External Quality Control

Chembio DPP HIV-Syphilis Reactive/Nonreactive Controls (Catalog #: 60-9555-0) are available separately for use with DPP HIV Syphilis. The controls are used to verify the operator's ability to properly perform the test and to interpret the results. The HIV-1/Syphilis Reactive Control will produce an HIV and syphilis reactive test result when read using the DPP Micro Reader. The HIV-2 Reactive Control will produce an HIV reactive and syphilis nonreactive test result when read using the DPP Micro Reader. The Non-reactive Control will produce a non-reactive test result for HIV and Syphilis when read using the DPP Micro Reader. Run the controls as described in the Test Procedure section for a plasma sample and follow the directions in the INTERPRETATION OF TEST RESULTS section of this product insert. It is the responsibility of each facility using DPP HIV-Syphilis to establish an adequate quality assurance program to ensure the performance of the device under specific locations and conditions of use.

RUN THE KIT CONTROLS UNDER THE FOLLOWING CIRCUMSTANCES:

- Each new operator prior to performing tests on patient samples
- When opening a new test kit lot
- Whenever a new shipment of test kits is received
- If the temperature of the test storage area falls outside of 2 to 25°C (36 to 77°F)
- If the temperature of the testing area falls outside of 18 to 25°C (64 to 77°F)
- At periodic intervals as indicated by the user facility

PERFORMANCE CHARACTERISTICS

Overall Summary

The performance of DPP HIV-Syphilis was evaluated from May 2016 to November 2019 with samples prospectively collected and tested from 2,762 individuals at ten (10) geographically distinct study sites within the United States. The study sites included HIV/STD Testing Clinics/ Outreach Centers, Primary Care Clinics, Obstetrics and Gynecology (OB/GYN) Centers and an Outpatient Addiction Treatment Center.

The HIV performance of DPP HIV-Syphilis was evaluated using samples collected from five groups of individuals: known infected with HIV-1 only, known positive for syphilis only, known positive for both HIV-1 and syphilis, at high risk for infection with HIV-1 and syphilis, and at low risk for infection with HIV-1 and syphilis.

The performance of the DPP HIV-Syphilis for detecting treponemal antibodies was evaluated using samples collected from four groups of individuals: those presenting for routine syphilis testing, those known positive for HIV-1 at enrollment, pregnant women, and those previously diagnosed with syphilis.

The clinical performance from the intended use population is summarized below for DPP HIV-Syphilis.

HIV Performance

Matrix	Sensitivity % (Ratio) (95% Cl)	Specificity % (Ratio) (95% CI)	
Capillary (Fingerstick) Whole Blood	99.4% (635/639) (98.4-99.8%)	99.6% (1352/1357) (99.1-99.8%)	
Venous Whole Blood	99.5% (635/638) (98.6-99.8%)	99.5% (1352/1359) (98.9-99.8%)	
Plasma	99.3% (405/408) (97.9-99.7%)	99.6% (902/906) (98.9-99.8%)	

Treponemal Test Line Performance

Matrix	Positive Percent Agreement % (Ratio) (95% Cl)	Negative Percent Agreement % (Ratio) (95% Cl)	
Capillary (Fingerstick) Whole Blood	94.7% (108/114) (89.0-97.6%)	95.5% (1116/1168) (94.2-96.6%)	
Venous Whole Blood	96.5% (110/114) (91.3-98.6%)	94.3% (1100/1166) (92.9-95.5%)	
Plasma	96.8% (60/62) (89.0-99.1%)	93.9% (1034/1101) (92.3-95.2%)	

HIV-1 SENSITIVITY Capillary (Fingerstick) Whole Blood

The sensitivity of DPP HIV-Syphilis to detect HIV-1 infection in fingerstick whole blood was evaluated using 619 samples from individuals known to be infected with HIV-1, 151 of which were known positive for both HIV-1 and syphilis, and 468 were known positive for HIV-1 only. All 619 samples were confirmed HIV-1 positive via HIV 1/2 Ag/Ab EIA. Six hundred fifteen (615) samples out of 619 tested HIV reactive using DPP HIV-Syphilis.

In addition, samples from 91 individuals known positive for syphilis only, from 728 individuals at high risk for HIV and syphilis, and from 558 individuals at low risk for HIV and syphilis were tested. Samples from these groups were tested for HIV via an HIV 1/2 Ag/Ab EIA and if reactive were confirmed using an HIV-1/HIV-2 differentiation assay. Of the 91 known positive syphilis only individuals, 6 were confirmed HIV positive, of the 728 high risk individuals, 13 were confirmed HIV positive, and of the 558 low risk individuals, 1 was confirmed HIV positive. All 20 of these samples were HIV reactive on DPP HIV-Syphilis.

The sensitivity of DPP HIV-Syphilis was evaluated using 639 (619 known HIV-1 positives and 19 true positives identified from the high-risk population and 1 true positive identified from the low-risk population) (see Table 1). Of these, 635 specimens tested reactive using DPP HIV-Syphilis (615 known positive, 19 high risk and 1 low risk) when fingerstick whole blood was tested in this study. In these studies, DPP HIV-Syphilis gave false non-reactive results for four confirmed positive specimens from known positive individuals when fingerstick whole blood specimens were tested. The calculated HIV sensitivity of DPP HIV-Syphilis for fingerstick whole blood was 635/639 = 99.4% (95% Confidence Interval = 98.4%-99.8%).

Table 1: Detection of Antibody to HIV-1 in Capillary Whole Blood (Fingerstick) Specimens from Individuals Known to Be Infected with HIV-1, and at High Risk for Infection with HIV-1

Dationt Infacted Status	DPP HIV-Syphi	Total	
Patient mected status	Reactive	Non-reactive	TOLAI
Positive	635	41	639
Negative	5	1352	1357
Total	640	1356	1996

¹ All 4 false non-reactive results were from individuals on ART.

Venous Whole Blood

The sensitivity of DPP HIV-Syphilis to detect HIV-1 infection in venous whole blood was evaluated using 618 samples from individuals known to be infected with HIV-1, 151 of which were known positive for both HIV-1 and Syphilis, and 467 were known positive for HIV-1 only. All 618 samples were confirmed HIV-1 positive via HIV 1/2 Ag/Ab EIA. Six hundred fifteen (615) samples out of 618 tested were HIV reactive using DPP HIV-Syphilis.

In addition, samples from 91 individuals known positive for syphilis only, from 729 individuals at high risk for HIV and Syphilis, and from 559 individuals at low risk for HIV and Syphilis were tested. Samples from these groups were tested for HIV via an HIV 1/2 Ag/Ab EIA and, if reactive, were confirmed using an HIV-1/HIV-2 Differentiation Assay. Of the 91 known positive syphilis only individuals, 6 were confirmed HIV positive, of the 728 high risk individuals, 13 were confirmed HIV positive, and of the 559 low risk individuals, 1 was confirmed HIV positive. All 20 of these samples were HIV reactive on DPP HIV-Syphilis.

The sensitivity of the DPP HIV-Syphilis was evaluated using 638 (618 known HIV-1 positives and 19 true positives identified from the high-risk population and 1 true positive identified from the low risk population) (see Table 2). Of these, 635 specimens tested reactive using DPP HIV-Syphilis (615 known positive, 19 high risk and 1 low risk) when venous whole blood was tested in this study. In these studies, DPP HIV-Syphilis gave false non-reactive results for three confirmed positive specimens from known positive individuals when fingerstick whole blood specimens were tested. The calculated HIV sensitivity of DPP HIV-Syphilis for venous whole blood was 635/638 = 99.5% (95% Confidence Interval = 98.6%-99.8%).

Table 2: Detection of Antibody to HIV-1 in Venous Whole Blood Specimens from Individuals Known to Be Infected with HIV-1, and at High Risk for Infection with HIV-1

	DPP HIV-Syphi	Total	
Patient mected status	Reactive	Non-reactive	TOLAI
Positive	635	31	638
Negative	7	1352	1359
Total	642	1355	1997

¹ Of these 3 false non-reactive individuals, 2 were on ART.

Potassium-EDTA Plasma

The sensitivity of DPP HIV-Syphilis to detect HIV-1 infection in plasma was evaluated using 398 samples from individuals known to be infected with HIV-1, 101 of which were known positive for both HIV-1 and syphilis, and 297 were known positive for HIV-1 only. All 398 samples were confirmed HIV-1 positive via HIV 1/2 Ag/Ab EIA. Three hundred ninety-five (395) samples out of 398 tested HIV reactive using DPP HIV-Syphilis.

In addition, samples from 75 individuals known positive for syphilis only, from 422 individuals at high risk for HIV and syphilis, and from 419 individuals at low risk for HIV and syphilis were tested. Samples from these groups were tested for HIV via an HIV 1/2 Ag/Ab EIA and if reactive were confirmed using an HIV-1/HIV-2 Differentiation Assay. Of the 75 known positive for syphilis only individuals, 5 were confirmed HIV positive, of the 422 High risk individuals, 4 were confirmed HIV positive, and of the 419 Low risk individuals, 1 was confirmed HIV positive. All 10 of these samples were HIV reactive on DPP HIV-Syphilis.

The sensitivity of DPP HIV-Syphilis was evaluated using 408 (398 known HIV-1 positives and 9 true positives identified from the high-risk population and 1 true positive identified from the low risk population) (see Table 3). Of these, 405 specimens tested reactive using DPP HIV-Syphilis (395 known positive, 9 high risk and 1 low risk) when plasma was tested in this study. In these studies, DPP HIV-Syphilis gave false non-reactive results for three confirmed positive specimens from known positive individuals when plasma specimens were tested. The calculated HIV sensitivity of DPP HIV-Syphilis for plasma was 405/408 = 99.3% (95% Confidence Interval = 97.9%-99.7%).

Table 3: Detection of Antibody to HIV-1 in Plasma Specimens from Individuals Known to Be Infected with HIV-1, and at High Risk for Infection with HIV-1

Detient Infected Status	DPP HIV-Syphi	Total	
Fatient metted status	Reactive	Non-reactive	Total
Positive	405	31	408
Negative	4	902	906
Total	409	905	1314

¹ All 3 false non-reactive results were from individuals on ART.

Reactivity with HIV-1 Specimens of Different Virus Subtypes

To assess the ability of DPP HIV-Syphilis to detect HIV-1 antibodies directed to different HIV-1 group M subtypes and HIV-1 Group "O", a total of 213 specimens (serum/plasma) from different worldwide geographical regions were tested. All 213 specimens were Reactive with DPP HIV-Syphilis for an overall sensitivity of 100% (95% CI = 98.3% to 100%). The results are presented in Table 4.

Table 4: Reactivity with HIV-1 Specimens from Various World Wide Geographic Regions

HIV Subtype	Number of Specimens	DPP HIV-Syphilis Reactive
А	30	30
AE	15	15
AG	30	30
В	5	5
B/D	1	1
С	39	39
D	19	19
F	9	9
G	20	20
н	7	7
J	2	2
К	3	3
CRF01/CRF15	1	1
CRF01_AE	2	2
CRF02_AG	3	3
CRF03_AB	2	2
G/CRF02	1	1
H/A1	1	1
K/CRF09	1	1
URF_01A1G	1	1
URF_A1C	2	2
URF_A1CD	2	2
URF_A1D	8	8
URF_CD	1	1
Recomb. Of F1, K	2	2
Recomb. Of G, K	1	1
Recomb. Of K, A1	1	1
0	4	4
TOTAL	213	213

Seroconversion Panels (Comparison to EIA)

Twenty-five commercial HIV-1 seroconversion panels were tested. Each panel consisted of sequential collections from a single individual who seroconverted. The table, summarized below, presents the days elapsed from the date of the initial bleed to the last negative sample and first reactive sample. Data are presented for two FDA licensed EIA tests and DPP HIV-Syphilis.

Table 5: Testing Seroconversion Panels using DPP HIV-Syphilis

	EIA	EIA 1 and DPP HIV-Syphilis		EIA 2 and DPP HIV-Syphilis		
	EIA 1 Repeatedly Reactive Test Result on Day:	DPP HIV-Syphilis Repeatedly Reactive Test Result on Day:	Difference in Days to Anti-HIV Reactive Result: EIA1 Minus DPP HIV-Syphilis	EIA 2 Repeatedly Reactive Test Result on Day:	DPP HIV-Syphilis Repeatedly Reactive Test Result on Day:	Difference in Days to Anti-HIV Reactive Result: EIA2 Minus DPP HIV-Syphilis
PRB917	60	65	-5	72	65	7
PRB924	33	35	-2	ND	35	-
PRB927	28	33	-5	40	33	7
PRB929	25	28	-3	28	28	0
PRB930	7	10	-3	10	10	0
PRB939	103	103	0	103	103	0
PRB970	10	14	-4	10	14	-4
PRB944	14	14	0	ND	14	-
PRB945	13	20	-7	ND	20	-
PRB947	11	20	-9	20	20	0
PRB955	12	14	-2	14	14	0
PRB967	17	19	-2	17	19	-2
PRB968	28	33	-5	28	33	-5
PRB969	70	72	-2	70	72	-2
9014	10	10	0	24	10	14
9031	146	153	-7	157	153	4
9032	24	49	-25	29	49	-20
9075	30	30	0	30	30	0
9077	57	52	5	52	52	0
12007	117	126	-9	126	126	0
9079	47	57	-10	47	57	-10
HIV-002	31	33	-2	NT	33	N/A
HIV-003	69	76	-8	NT	76	N/A
HIV-007	47	47	0	NT	47	N/A

ND = Not Detected; NT = Not Tested; N/A = Not Applicable

HIV-2 SENSITIVITY

The sensitivity of DPP HIV-Syphilis to detect HIV-2 antibody was determined by testing 210 serum/plasma specimens that were positive for HIV-2 antibodies only. These specimens were obtained from repository sources. A total of 546 specimens from an area endemic for HIV-2 infection were also tested. All specimens reactive with DPP HIV-Syphilis were also reactive by FDA approved/licensed HIV 1/2 Assays. The sensitivity of DPP HIV-Syphilis for detection of antibodies to HIV-2 in these studies were calculated to be 210/210 = 100% with the 95% confidence interval extending from 98.3 to 100%.

Table 6: Detection of Antibody to HIV-2 in Known HIV-2 Reactive Specimens and Endemic Samples

Study Population	Samples	DPP HIV-Syphilis Reactive	True HIV-2 Positive Only ¹
Known HIV-2 Positive	210	210	210
Endemic Samples	546	196 ²	0
Total	756	406	210

¹Confirmation based on results using a research use HIV-2 Western Blot.

²Of these 196 reactive specimens, 91 were reactive on HIV-1 WB only, 105 were reactive on HIV-1 and HIV-2 WB.

HIV SPECIFICITY

Capillary (Fingerstick) Whole Blood

The HIV specificity of DPP HIV-Syphilis was evaluated by testing fingerstick blood specimens from 91 syphilis known positive only, 728 High risk and 558 individuals Low risk for HIV and syphilis at 7 clinical study sites. Specimens were tested with an HIV 1/2 Ag/Ab EIA and if non-reactive were determined Negative for HIV.

Specimens from 6 syphilis known positive, 13 high risk and 1 low risk individuals were reactive on a licensed HIV-1/2 Ag/Ab EIA and were excluded from these calculations. Based on these studies, the HIV specificity of DPP HIV-Syphilis in capillary (fingerstick) whole blood specimens was calculated to be 1352/1357 = 99.6% with the 95% confidence interval extending from 99.1 to 99.8%.

Table 7: Performance of DPP HIV-Syphilis on Capillary Whole Blood (Fingerstick) Specimens from Individuals Presumed to Be Negative for HIV-1 Infection

Study Population	Samples	True HIV Negative	DPP HIV-Syphilis Non-reactive
Syphilis Known Positive	91	85	85
High Risk for HIV	728	715	711
Low Risk for HIV	558	557	556
TOTAL	1377	1357	1352

Venous Whole Blood

The HIV specificity of DPP HIV-Syphilis was evaluated by testing venous blood specimens from 91 syphilis known positive only, 729 high risk and 559 individuals low risk for HIV and syphilis at 7 clinical study sites. Specimens were tested with an HIV 1/2 Ag/Ab EIA and if non-reactive were determined Negative for HIV.

Specimens from 6 syphilis known positive, 13 high risk and 2 low risk individuals were reactive on a licensed HIV-1/2 Ag/Ab EIA and were excluded from these calculations. Based on these studies, the HIV specificity of DPP HIV-Syphilis in capillary (fingerstick) whole blood specimens was calculated to be 1352/1359 = 99.5% with the 95% confidence interval extending from 98.9 to 99.8%.

Table 8: Performance of DPP HIV-Syphilis on Venous Whole Blood Specimens from Individuals Presumed to be Negative for HIV-1 Infection

Study Population	Samples	True HIV Negative	DPP HIV-Syphilis Non-reactive
Syphilis Known Positive	91	85	84
High Risk for HIV	729	716	711
Low Risk for HIV	559	558	557
TOTAL	1379	1359	1352

Plasma

The HIV specificity of DPP HIV-Syphilis was evaluated by testing plasma specimens from 91 syphilis known positive only, 729 at high risk and 559 individuals at low risk for HIV and syphilis at 7 clinical study sites. Specimens were tested with an HIV 1/2 Ag/Ab EIA and if non-reactive were determined Negative for HIV.

Specimens from 5 syphilis known positive, 4 high risk and 1 low risk individuals were reactive on a licensed HIV-1/2 Ag/Ab EIA and were excluded from these calculations. Based on these studies, the HIV specificity of DPP HIV-Syphilis in capillary (fingerstick) whole blood specimens was calculated to be 902/906 = 99.6% with the 95% confidence interval extending from 98.9 to 99.8%. Table 9: Performance of DPP HIV-Syphilis on Plasma from Individuals Presumed to be Negative for HIV-1 Infection

Study Population	Samples	True HIV Negative	DPP HIV-Syphilis Non-reactive
Syphilis Known Positive	75	70	70
High Risk for HIV	422	418	415
Low Risk for HIV	419	418	417
TOTAL	916	906	902

Treponemal Test Line Performance in Intended Use Population

The treponemal test line performance of DPP HIV-Syphilis was evaluated in fingerstick, venous whole blood and plasma samples prospectively collected and tested from 1529 individuals in the intended use population. From these 1529 individuals, 1282 fingerstick whole blood samples were available for testing (629 female, 653 male, 16–87 years old), 1280 venous whole blood samples were available for testing (627 female, 653 male, 16–87 years old), and 1163 plasma samples were available for testing (638 female, 525 male, 16–91 years old). The demographics of the intended use population for each study cohort are presented in the following table.

Table 10: Study Cohort Demographics for Treponemal Test Line Performance

Matrix	Cohort	Number of Subjects	Number of Females	Number of Males	Age Range (Years)
	Routine Syphilis	704	200	504	16-87
Einen untiele	HIV Positive at Enrollment	171	22	149	18-75
Fingerstick	Pregnant Women	407	407	N/A	18-43
	TOTAL	1282	629	653	16-87
Venous Blood	Routine Syphilis	704	200	504	16-87
	HIV Positive at Enrollment	171	22	149	18-75
	Pregnant Women	405	405	N/A	18-43
	TOTAL	1280	627	653	16-87
	Routine Syphilis	688	226	462	16-91
	HIV Positive at Enrollment	68	5	63	23-75
Plasma	Pregnant Women	407	407	N/A	18-43
	TOTAL	1163	638	525	16-91

Positive Percent Agreement with Reference Methods

The clinical performance of the treponemal test line of DPP HIV-Syphilis was evaluated by calculating the positive percent agreement and negative percent agreement of the assay with the final comparator result based on an algorithm of results from three commercially available FDA-cleared syphilis assays: a treponemal EIA, a non-treponemal assay (RPR) and a second treponemal assay (TPPA). Because the clinical diagnosis of syphilis must be supported by two reactive laboratory tests, consisting of a treponemal assay and a non-treponemal assay, or at least two treponemal assays, employing an algorithm of three syphilis tests to determine the comparator result presents information closest to the serological "truth".

The final comparator result was determined using a two out of three rule. The following table shows how the final comparator result was determined.

Table 11: Serologic Comparator Algorithm for Treponemal Antibodies

1 st Treponemal Test (EIA)	Non-Treponemal (RPR)	2 nd TreponemalTest (TPPA)	Final Comparator Result
		Reactive	Negative
Non-reactive	Non-reactive	Non-reactive	Negative
		Inconclusive	Negative
		Reactive	Positive
Non-reactive	Reactive	Non-reactive	Negative
		Inconclusive	Negative ¹
		Reactive	Positive
Reactive	Reactive	Non-reactive	Positive
		Inconclusive	Positive
		Reactive	Positive
Reactive	Non-reactive	Non-reactive	Negative
		Inconclusive	Positive ²
		Reactive	Positive
Equivocal	Non-reactive	Non-reactive	Negative
		Inconclusive	Indeterminate
		Reactive	Positive
Equivocal	Reactive	Non-reactive	Negative
		Inconclusive	Indeterminate

¹ The final comparator result of Negative was assigned based on the nonreactive treponemal test. There were no subjects with this serological profile among the study population.

² The final comparator result of Positive was assigned based on the reactive treponemal test. There were 5 subjects with this serological profile among the prospective study population.

A summary of the serological test profile for all prospectively-collected specimens in the intended use population is presented in the following table.

Table 12: Serologic Comparator Algorithm Result Profile for Syphilis in Intended Use Population

Treponemal Screen Assay (EIA)	Non-Treponemal (RPR)	2 nd Treponemal (TPAA)	Final Comparator Result	Number of Subjects ¹
NR	NR	N/A	Negative	1395
NR	R	R	Positive	0
NR	R	NR	Negative	2
NR	R	Inconclusive	Negative	0
R	R	N/A	Positive	58
R	NR	R	Positive	56
R	NR	NR	Negative	7
R	NR	Inconclusive	Positive	5
Equivocal	NR	R	Positive	0
Equivocal	NR	NR	Negative	2
Equivocal	NR	Inconclusive	Indeterminate	0
Equivocal	R	R	Positive	0
Equivocal	R	NR	Negative	0
Equivocal	R	Inconclusive	Indeterminate	0

NR= Non-reactive; R = Reactive; N/A = Test not performed

¹ Four subjects were nonreactive on the Treponemal Screen Assay but did not have enough sample remaining for additional testing required to complete serological comparator algorithm.

The comparison between DPP HIV-Syphilis result for treponemal antibodies and the final comparator results for prospectively-collected Fingerstick whole blood specimens in the intended use population is shown in the following tables (Table 13-14).

Table 13: Percent Agreement with Final Comparator Result for Treponemal Antibodies in Prospective Fingerstick Whole Blood Samples

DPP - <i>T. pallidum</i>	Reference (Final (Tetel		
Result	Positive for Syphilis Negative for Syphilis		lotai	
Reactive	108	52	160	
Non-reactive	6	1116	1122	
Total	114	1168	1282	

Positive percent agreement for DPP HIV-Syphilis for treponemal antibodies in the intended use population was 94.7% (108/114) with a 95% confidence interval of 89.0% to 97.6%. Negative percent agreement was 95.5% (1116/1168) with a 95% confidence interval of 94.2% to 96.6%.

Table 14: Percent Agreement with Final Comparator Result for Treponemal Antibodies in Fingerstick Whole Blood Samples, Stratified by Study Cohort

Cabart	Positive Percent Agreement (PPA)			Negative Percent Agreement (NPA)		
Conort	%	Ratio	95% CI	%	Ratio	95% CI
Routine Syphilis	92.5%	49/53	82.1-97.0%	97.1%	632/651	95.5-98.1%
HIV Positive at Enrollment	96.6%	57/59	88.5-99.1%	95.5%	107/112	90.0-98.1%
Pregnant Women	100.0	2/2	N/A	93.1%	377/405	90.2-95.2%
TOTAL	94.7%	108/114	89.0-97.6%	95.5%	1116/1168	94.2-96.6%

The comparison between DPP HIV-Syphilis result for treponemal antibodies and the final comparatorresults for prospectively-collected venous whole blood specimens in the intended use population is shown in the following tables (Table 15-16).

Table 15: Percent Agreement with Final Comparator Result for Treponemal Antibodies in Prospective Venous Whole Blood Samples

DPP - T. pallidum	Reference (Final (Tatal		
Result	Positive for Syphilis Negative for Syphilis		Total	
Reactive	110	66	176	
Non-reactive	4	1100	1104	
Total	114	1166	1280	

Positive percent agreement for DPP HIV-Syphilis in the intended use population was 96.5% (110/114) with a 95% confidence interval of 91.3% to 98.6%. Negative percent agreement was 94.3% (1100/1166) with a 95% confidence interval of 92.9% to 95.5%.

Table 16: Percent Agreement with Final Comparator Result for Treponemal Antibodies in Venous Whole Blood Samples, Stratified by Cohort

Calcut	Positive Percent Agreement (PPA)			Negative Percent Agreement (NPA)		
Conort	%	Ratio	95% CI	%	Ratio	95% CI
Routine Syphilis	96.2%	51/53	87.2-99.0%	96.3%	627/651	94.6-97.5%
HIV Positive at Enrollment	96.6%	57/59	88.5-99.1%	95.5%	107/112	90.0-98.1%
Pregnant Women	100%	2/2	N/A	90.8%	366/403	87.6-93.3%
TOTAL	96.5%	110/114	91.3-98.6%	94.3%	1100/1166	92.9-95.5%

The comparison between DPP HIV-Syphilis result for treponemal antibodies and the final comparator results for prospectively-collected plasma specimens in the intended use population is shown in the following tables (Table 17-18).

Table 17: Percent Agreement with Final Comparator Result for Treponemal Antibodies in Prospective Plasma Samples

DPP - <i>T. pallidum</i>	Reference (Final G	Total	
Result	Positive for Syphilis Negative for Syphilis		
Reactive	60	67	127
Non-reactive	2	1034	1036
Total	62	1101	1163

Positive percent agreement for DPP HIV-Syphilis in the intended use population was 96.8% (60/62) with a 95% confidence interval of 89.0% to 99.1%. Negative percent agreement was 93.9% (1034/1101) with a 95% confidence interval of 92.3% to 95.2%.

Table 18: Percent Agreement for *T. Pallidum* Antibodies in Plasma Samples, Stratified by Cohort

Cohort	Positive Percent Agreement (PPA)			Negative Percent Agreement (NPA)		
Conort	%	Ratio	95% CI	%	Ratio	95% CI
Routine Syphilis	94.9%	37/391	83.1-98.6%	95.1%	617/649 ²	93.1-96.5%
HIV Positive at Enrollment	100.0%	21/21	84.5-100.0%	97.9%	46/47	88.9-99.6%
Pregnant Women	100.0%	2/2	N/A	91.6%	371/405	88.5-93.9%
TOTAL	96.8%	60/62	89.0-99.1%	93.9%	1034/1101	92.3-95.2%

¹ Includes sample from 1 subject of Unknown HIV Status.

² Includes samples from 106 subjects of Unknown HIV Status.

Treponemal Test Line Performance in Subjects Previously Diagnosed with Syphilis

The treponemal test line performance of DPP HIV-Syphilis was evaluated in fingerstick, venous whole blood and plasma samples prospectively collected and tested from 162 individuals self-reported as previously diagnosed with syphilis. Fingerstick and venous whole blood samples were available for all subjects (33 female, 129 male, 18–77 years old), and plasma samples were available for testing for 129 of 162 subjects (30 female, 99 male, 18–77 years old). To determine the Final Comparator Result, all subjects were tested with two FDA cleared syphilis tests at minimum, a treponemal EIA and a non-treponemal assay (RPR). A third syphilis test (TPPA) was used if the first two tests disagreed. The comparator Result for prospectively-collected subjects that were previously diagnosed with syphilis is shown in the following table (Table 19).

Table 19: Percent Agreement with Final Comparator Result for Treponemal Antibodies in Subjects Previously Diagnosed with Syphilis

A de Audra	Positive Percent Agreement (PPA)			Negative Percent Agreement (NPA)		
watrix	%	Ratio	95% CI	%	Ratio	95% CI
Capillary (Fingerstick) Whole Blood	93.9%	108/115	88.0-97.0 %	87.2%	41/47	74.8-94.0%
Venous Whole Blood	96.5%	111/115	91.4-98.6%	85.1%	40/47	72.3-92.6%
Plasma	97.8%	91/93	92.5-99.4%	83.3%	30/36	68.1-92.1%

Reactivity with Medically Diagnosed Specimens

To assess the performance of the DPP HIV-Syphilis in detecting *Treponema pallidum* antibodies using various medically staged syphilis specimens, 163 samples representing various clinical stages of syphilis diagnosis (primary, secondary, and latent) and treatment status were tested. The DPP HIV-Syphilis was reactive in all 163 patients tested (Table 20).

Table 20: Summary of DPP HIV-Syphilis Results for Treponemal antibodies in Medically Staged Syphilis Samples

Syphilis Stage	Treatment Status	N	DPP HIV-Syphilis Reactive
Primany	Treated	18	100%
Primary	Untreated	10	100%
Georgedami	Treated	33	100%
Secondary	Untreated	30	100%
	Treated	42	100%
Latent	Untreated	30	100%
	TOTAL	163	100%

Reactivity for Treponemal Antibodies with Prospectively Collected Pregnant Women Specimens

The treponemal test line performance of DPP HIV-Syphilis was evaluated in fingerstick, venous whole blood and plasma samples prospectively collected and tested from 407 pregnant women. Fingerstick and plasma were available for all subjects (18–43 years old), and venous whole blood samples were available for testing for 405 of 407 subjects (18–43 years old). To determine the Final Comparator Result, all pregnant women were tested with two FDA cleared syphilis tests at minimum, a treponemal EIA and a non-treponemal assay (RPR). A third syphilis test (TPPA) was used if the first two tests disagreed. The performance of the treponemal test line of DPP HIV-Syphilis is presented by pregnancy trimester in the table below.

Table 21: Performance of DPP HIV-Syphilis for Treponemal Antibodies with Samples Prospectively Collected from Pregnant Women

	Percent Agreement with the Final Comparator Result							
Trimester	Positive ا	Percent Agreeme	ent (PPA)	Negative Percent Agreement (NPA)				
	۶	6 (Ratio) (95% Cl	I)	% (Ratio) (95% Cl)				
	Fingerstick	Venous Blood	Plasma	Fingerstick	Venous Blood	Plasma		
1 st	100 (1/1)	100 (1/1)	100 (1/1)	92.1 (140/152)	90.8 (138/152)	92.1 (140/152)		
	(20.7–100)	(20.7–100)	(20.7–100)	(86.7–95.4)	(85.1–94.4)	(86.7–95.4)		
2 nd	100 (1/1)	100 (1/1)	100 (1/1)	96.5 (109/113)	93.8 (106/113)	91.2 (103/113)		
	(20.7–100)	(20.7–100)	(20.7–100)	(91.3–98.6)	(87.8–97.0)	(84.5–95.1)		
3 rd	N/A (0/0)	N/A (0/0)	N/A (0/0)	91.4 (128/140) (85.6–95.0)	88.4 (122/138) (82.0–92.7)	91.4 (128/140) (85.6–95.0)		

Reactivity for Treponemal Antibodies with Retrospectively Collected Pregnant Women Specimens

To assess the performance of DPP HIV-Syphilis in detecting treponemal antibodies, 34 retrospectively collected samples (serum) from pregnant women that were presumed positive for Syphilis infection were tested. These samples included 12 samples that had been tested using an FDA cleared test for non-treponemal antibodies (RPR with titer) and 22 samples that had been tested using FDA cleared tests for treponemal antibodies (IgG) as well as non-treponemal antibodies (RPR with titer).

DPP HIV-Syphilis demonstrated a 100% reactivity for treponemal antibodies in all 34 samples from pregnant women that were determined reactive by laboratory testing with FDA cleared tests for syphilis (Table 22).

Table 22: Performance of DPP HIV-Syphilis for Treponemal Antibodies with Samples from Pregnant Women presumed positive for Syphilis

Syphilis Stage	Treatment Status	Trimester	N	DPP HIV-Syphilis Reactive
	Treated	Unknown	0	N/A
Primary	Untreated	Unknown	3	100%
	Treated	Unknown	0	N/A
Secondary	Untreated	Unknown	1	100%
	Treated	Unknown	0	N/A
Early Latent Untreated	Untreated	Unknown	5	100%
	Treated	Unknown	0	N/A
Latent	Untreated	Unknown	3	100%
] st	8	100%
Unknown	Unknown	2 nd	6	100%
		3 rd	8	100%
	TOTAL		34	100%

ANALYTICAL SPECIFICITY

Effect of Unrelated Medical Conditions on Analytical Sensitivity and Specificity

To evaluate the effect of unrelated medical conditions on the performance of DPP HIV-Syphilis, 438 samples containing antibodies against Cirrhosis, CMV (IgM), Dialysis, Syphilis, dsDNA, EBV (IgG), HAV (IgM), HBV Ag, HCV Ab, HIV Ab, HSV-1 (IgG), HSV-2 (IgG), HTLV I/ II Ab, Leptospirosis, Rheumatoid Factor, SLE, Tuberculosis, VSV IgG, Cardiolipin (IgG and IgM), specimens containing Human Anti-Mouse Antibodies (HAMA), specimens from individuals who are intravenous drug users (IVDU), multiparous females, pregnant females, those who recently received an influenza vaccine, and individuals with Scleroderma, Hypergammaglobulinemia (IgA, IgE, IgG, and IgM), Antiphospholipid Syndrome, Chlamydia, and Gonorrhea were tested with the DPP HIV-Syphilis.

Table 23: Unrelated Medical Conditions

Unrelated Medical Condition	Number	# Reactive by DPP (HIV)	# Reactive by DPP (Treponemal)
Cirrhosis	10	0	0
Cytomegalovirus (CMV) IgM	70	0	71
Dialysis	10	0	0
Double Stranded DNA (dsDNA) Ab	72	0	8 ²
Epstein–Barr Virus (EBV) IgG	10	0	0
Hepatitis A Virus (HAV) IgM	10	0	0
Hepatitis B Virus (HBV) Ag	10	0	0
Hepatitis C Virus (HCV) Ab	10	0	0
HIV Ab	10	10	0
Herpes Simplex Virus (HSV)-1 IgG	10	0	0
Herpes Simplex Virus (HSV)-2 IgG	10	0	0
Human T-Lymphotropic Virus (HTLV) I/II	10	0	0
Syphilis	10	0	10
Lipemic	10	0	0
Lyme	10	0	0
Influenza Vaccine	10	0	0
Pregnant Females	12	0	0
Multiparous Females	10	0	0
Rheumatoid Factor	13	0	0
Varicella Zoster Virus (VZV) IgG	11	0	0
Tuberculosis	15	0	0
Drug Users (IVDU)	13	0	0
Leptospirosis	11	0	0
Systemic Lupus Erythematosus (SLE)	44	0	13
Scleroderma	10	0	0
НАМА	10	0	0
Cardiolipin IgG	7	0	0
Cardiolipin IgM	8	0	0
Hypergammaglobulinemia IgA	9	0	0
Hypergammaglobulinemia IgE	10	0	0
Hypergammaglobulinemia IgG	10	0	0
Hypergammaglobulinemia IgM	10	0	0
Antiphospholipid Syndrome	3	0	0
Chlamydia	10	0	0
Gonorrhea	10	0	0
Total	508	10	26

¹A total 70 CMV IgM specimens were tested on DPP HIV-Syphilis, of which 7 samples yielded reactive results on the treponemal test line for an estimated cross-reactivity rate of 10.0% (7/70).

²A total of 72 dsDNA specimens were tested on DPP HIV-Syphilis, of which 8 yielded reactive results on the treponemal test line for an estimated cross-reactivity rate of 11.1% (8/72).

³A total of 44SLE specimens were tested on DPP HIV-Syphilis, of which 1 yielded reactive results on the treponemal test line for an estimated cross-reactivity rate of 2.3% (1/44).

Effect of Interfering Substances on Analytical Sensitivity and Specificity

The effect of the following potentially interfering substances on assay performance was tested using 100 specimens representing potentially interfering substances. Interferences were tested up to the listed concentrations and no impact on results was observed.

Interfering Substance	Concentration Tested
Hemoglobin Samples	0.98–500 mg/dL
Triglyceride/Triolin	5.86–3,000 mg/dL
Bilirubin Mixed Isomer	0.04–20 mg/dL
Total Protein (HAS)	6.0–11.0 g/dL
E. coli	98–50,000 CFU/mL
EDTA	1.56–800 mg/dL
Sodium Citrate	1.95–1,000 mg/dL
Lithium Heparin	15.63-8,000 mg/dL
Sodium Heparin	15.63–8,000 mg/dL
Candida albicans	44–22,500 cells/mL

Table 24: Interfering Substances

Reproducibility in Plasma

Reproducibility studies were performed to demonstrate the inter-day reproducibility of DPP HIV-Syphilis in plasma. This study was conducted at three laboratory sites using a panel of eight blinded plasma samples representing the following: non-reactive, HIV-1 low reactive, HIV-2 low reactive, treponemal antibody low reactive, HIV-1 and treponemal antibody low reactive, HIV-1 high reactive, HIV-2 high reactive, and treponemal antibody high reactive. Each panel was run on 3 lots of DPP HIV-Syphilis on 3 separate days by 3 separate operators at each site. Results were read at 10 minutes, using the DPP Micro Reader. A total of 648 data points was taken per test line (HIV and treponemal). The results of the reproducibility study in plasma are presented in Tables 25 and 26 below.

Table 25: Reproducibility in Plasma: All Sites, All Operators, All Days

Sample	HIV Test Line % Agreement with Expected Result (# Reactive/# Tested)	Treponemal Test Line % Agreement with Expected Result (# Reactive/# Tested)
HIV-1 Low Reactive	100% (81/81)	100% (0/81)
HIV-2 Low Reactive	100% (81/81)	100% (0/81)
Treponemal Antibody Low Reactive	100% (0/81)	100% (81/81)
HIV-1 & Treponemal Antibody Low Reactive	100% (81/81)	98.8% (80/81)
HIV-1 High Reactive	100% (81/81)	100% (0/81)
HIV-2 High Reactive	100% (81/81)	100% (0/81)
Treponemal Antibody High Reactive	100% (0/81)	98.8% (80/81)
Non-reactive	100% (0/81)	98.8% (1/81)

Table 26: Reproducibility in Plasma, By Sites

Sample	ן (# Ex;	HIV Test Line pected/# Te	e sted)	Treponemal Test Line (# Expected/# Tested)		
	Site 1	Site 2	Site 3	Site 1	Site 2	Site 3
HIV-1 Low Reactive	27/27	27/27	27/27	27/27	27/27	27/27
HIV-2 Low Reactive	27/27	27/27	27/27	27/27	27/27	27/27
Treponemal Antibody Low Reactive	27/27	27/27	27/27	27/27	27/27	27/27
HIV-1 & Treponemal Antibody Low Reactive	27/27	27/27	27/27	26/27	27/27	27/27
HIV-1 High Reactive	27/27	27/27	27/27	27/27	27/27	27/27
HIV-2 High Reactive	27/27	27/27	27/27	27/27	27/27	27/27
Treponemal Antibody High Reactive	27/27	27/27	27/27	27/27	26/27	27/27
Non-reactive	27/27	27/27	27/27	27/27	26/27	27/27

Reproducibility in Venous Whole Blood

Reproducibility studies were performed to demonstrate the reproducibility of DPP HIV-Syphilis in venous whole blood. This study was conducted at three laboratory sites using a panel of six blinded venous whole blood samples representing the following: non-reactive, HIV-1 low reactive, HIV-2 low reactive, treponemal antibody low reactive, HIV-1 near cut-off (borderline), and treponemal antibody near cut-off (borderline). Each panel was run in duplicate on 5 separate days, twice per day, by 2 separate operators at each site (6 total). Testing was performed according to the Product Insert of DPP HIV-Syphilis. Results were read at 10 minutes using the DPP Micro Reader. The results of the study are presented in Tables 27 and 28 below.

Table 27: Reproducibility in Venous Whole Blood: All Sites, All Operators, All Days

Sample	HIV Test Line % Agreement with Expected Result (# Reactive/# Tested)	Treponemal Test Line % Agreement with Expected Result (# Reactive/# Tested)
Low Reactive HIV-1	100% (120/120)	97.5% (3/120)
Low Reactive HIV-2	100% (120/120)	100% (0/120)
Low Reactive Syphilis	100% (0/120)	100% (120/120)
Non-reactive	100% (0/120)	99.2% (1/120)
Near Cutoff Reactive HIV-1	93.3% (112/120)	99.2% (1/120)
Near Cutoff Reactive Syphilis	100% (0/120)	95.8% (115/120)

Table 28: Reproducibility in Venous Whole Blood, By Sites

Sample	+ # Ex;	HV Test Line pected/# Te	e sted)	Treponemal Test Line (# Expected/# Tested)		
	Site 1	Site 2	Site 3	Site 1	Site 2	Site 3
Low Reactive HIV-1	40/40	40/40	40/40	0/40	0/40	3/40
Low Reactive HIV-2	40/40	40/40	40/40	0/40	0/40	0/40
Low Reactive Syphilis	0/40	0/40	0/40	40/40	40/40	40/40
Non-reactive	0/40	0/40	0/40	1/40	0/40	0/40
Near Cutoff Reactive HIV-1	37/40	40/40	35/40	1/40	0/40	0/40
Near Cutoff Reactive Syphilis	0/40	0/40	0/40	38/40	40/40	37/40

CLIA WAIVER Study

The performance of the DPP HIV-Syphilis Assay was evaluated in prospective studies at 5 geographically diverse sites representative of CLIA waived settings. At each site the DPP HIV-Syphilis testing was conducted by operators who had no laboratory experience and were representative of users at CLIA waived sites. The 50 operators (intended users) who participated in the study were not given any training on the use of the test. While a total of 1385 subjects were enrolled in these studies, there were 192 fingerstick specimens excluded due to patient ineligibility or sample collection and handling issues, with one sample generating an invalid result on the DPP HIV-Syphilis Test, leaving a total of 1193 fingerstick specimens to be included in the evaluation of the assay performance. The subjects were tested with the DPP HIV-Syphilis and the comparator method and their HIV or Syphilis status was not known to the operators. The HIV status was determined by a comparator method which consists of an FDA approved EIA with supplemental HIV-1/HIV-2 Differentiation and PCR assays as required. The Syphilis status was determined via the Serological Comparator Algorithm (Table 11). The result of the DPP HIV-Syphilis was compared to the status of the subject. The positive percent agreement (PPA) and negative percent agreement (NPA) between DPP HIV-Syphilis and the status of the study subjects was calculated for HIV and Syphilis and is presented in Tables 29 and 30. The overall invalid rate was 0.1% (1/1194) with 95% CI: 0.0% to 0.5%.

Table 29: HIV Performance of the DPP HIV-Syphilis with fingerstick whole blood specimens by	
untrained users in a CLIA Waived setting	

Population	N	ТР	FN	TN	FP	PPA (95% CI)	NPA (95% CI)
Unknown HIV status at Enrollment	484	10	0	472	2	100% (72.3 - 100%)	99.6% (98.5 - 99.9%)
Known HIV positive at Enrollment	676	670	61	0	0	99.1% (98.1 - 99.6%)	N/A
Combined	1160	680	61	472	2	99.1% (98.1 - 99.6%)	99.6% (98.5 - 99.9%)

¹Two of the DPP HIV negative samples were from HIV Known Positive subjects that were HIV-1 Indeterminate or Negative via HIV-1/HIV-2 Differentiation Assay and HIV-1 RNA was not detectable via Nucleic Acid Test (NAT).

N=Included Subjects, TP= True Positive, TN=True Negative, FN=False Negative, FP= False Positive

Table 30: Treponemal Test Line Performance of the DPP HIV-Syphilis with fingerstick whole blood specimens by untrained users in a CLIA Waived setting

	Positive Percent Agreement	Negative Percent Agreement		
Population	Pos % (Ratio) (95% CI)	Neg % (Ratio) (95% CI)		
Subjects tested for Syphilis	95.8% (295/308) (92.9% - 97.5%)	95.0% (509/536) (92.8% - 96.5%)		

Additionally, the performance of the assay with weakly reactive samples was demonstrated in a reproducibility study (described above) testing weakly reactive samples by 6 operators at 3 sites in a CLIA Waived setting. The samples were prepared in whole blood and included one HIV reactive sample and one Treponemal (syphilis) antibody reactive sample, each prepared at analyte concentrations near the limit of detection (LoD) of the assay. As described above, the samples were provided to the operators in randomly coded panels so that they were unaware of the sample status. Table 31 below shows the performance of the test with samples near the cutoff of the assay in the hands of intended users.

Table 31: Performance of the DPP HIV-Syphilis Run by Intended Users with Near Cutoff Reactive Samples

	HIV Test Line					Treponemal Test Line				
Sample	Reactive/Total (% Agreement with Expected Result)				Reactive/Total (% Agreement with Expected Result)					
	Site 1	Site 2	Site 3	Total	95% CI	Site 1	Site 2	Site 3	Total	95% CI
Near Cutoff HIV-1 (1-2x LoD)	35/40 (87.5%)	37/40 (92.5%)	40/40 (100%)	112/120 (93.3%)	87.4- 96.6%	0/40 (100%)	1/40 (97.5%)	0/40 (100%)	1/120 (99.2%)	95.4-99.9%
Near Cutoff Syphilis (1-2x LoD)	0/40 (100%)	0/40 (100%)	0/40 (100%)	0/120 (100%)	96.9-100%	37/40 (92.5%)	38/40 (95%)	40/40 (100%)	115/120 (95.8%)	90.6-98.2%
Non Reactive	0/40 (100%)	0/40 (100%)	0/40 (100%)	0/120 (100%)	96.9-100%	0/40 (100%)	1/40 (97.5%)	0/40 (100%)	1/120 (99.2%)	95.4-99.9%

Analytical flex studies were conducted using the risk analysis as a guide. The studies demonstrated that the test is insensitive to stresses of environmental conditions and potential user errors.

REFERENCES

- 1. Centers for Disease Control and Prevention (CDC) Universal Precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988; 37(24):377-388.
- 2. Essex, M. (1999) Human immunodeficiency viruses in the developing world. Adv Virus Res 53: 71-88.
- 3. Kanki, P.J., Hopper, J.R. and Essex, M. (1987) The origins of HIV-1 and HTLV-4/HIV/2. Ann N Y Acad Sci 511: 370-375.
- 4. Nicoll, A., Gill, O.N. (1999) The global impact of HIV infection and disease. Commun Dis Publ Health 2: 85-95.
- 5. Valdiserri R.O., Holtgrave, D.R., West, G.R. (1999) Promoting early diagnosis and entry into care. AIDS 13: 2317-2330.
- Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time until emergence of HIV test reactivity following infection with HIV-1: Implications for interpreting test results and retesting after exposure. Clin Infect Dis 2017;64(1):53-9. PubMed.
- 7. Centers for Disease Control and Prevention (CDC). HIV Basics: Types of HIV Tests, Retrieved from https://www.cdc.gov/hiv/basics/hiv-testing/test-types.html. Accessed 2020 Aug 10.
- 8. Centers for Disease Control and Prevention (CDC). (2016) Implementing HIV Testing in Nonclinical Settings: A Guide for HIV Testing Providers. 2016 Mar 2:30-31.
- 9. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at http://dx.doi.org/10.15620/cdc.23447. Published June 27, 2014. Accessed 2020 Aug 10.
- 10. Centers for Disease Control and Prevention (CDC). 2015 Sexually Transmitted Diseases Treatment Guidelines. MMWR 2015; 64(3); 34-48.
- 11. Wassermann, A., Neisser, A., Bruck, C., Eine serodiagnostische reaktion bei Syphilis, Dtsch Med Wochenschr, 32:745-6, 1906.
- 12. Matthews, H.M., Yang, T.K., Jenkin, H.M., Unique lipid composition of Treponema pallidum (Nichols virulent strain), Infect Immun, 24:713-19, 1979.
- Seña AC, White BL, Sparling PF. Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clin Infect Dis. 2010;51(6):700-708. doi:10.1086/655832
- Centers for Disease Control and Prevention (CDC). Discordant Results from Reverse Sequence Syphilis Screening – Five Laboratories, United States, 2006—2010. MMWR 2011; 60(5); 133-137.
- Centers for Disease Control and Prevention (CDC). National Notifiable Diseases Surveillance System 2018 Syphilis (Treponema pallidum) Case Definition. Retrieved from https://wwwn.cdc.gov/nndss/ conditions/syphilis/case-definition/2018/. Accessed 2020 Aug 10.
- 16. Sellati TJ et al. Virulent Treponema pallidum, lipoprotein, and synthetic lipopeptides induce CCR5 on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1. J Infect Dis 2000 Jan; 181:283.
- Centers for Disease Control and Prevention (CDC). Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV and HIV Recommendations for Postexposure Prophylaxis. MMWR 2001; 50(RR-11):1-42.
- CDC Update U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis. Infection Control and Hospital Epidemiology. 2013 Sep; 34 (9): 875-92.
- Centers for Disease Control and Prevention (CDC). Revised Guidelines for HIV Counseling, Testing and Referral and Revised Recommendations for HIV Screening of Pregnant Women. MMWR 2001; 50(19);32-35.

Ordering Information

Product	Catalog Number
DPP® HIV-Syphilis	65-9502-0
DPP® HIV-Syphilis Rapid Test Control Pack	60-9555-0
DPP® Micro Reader for Use with DPP® HIV-Syphilis	70-1056-0

For Product Information, Literature and/or SDS please email: info@chembio.com

Manufactured by: CHEMBIO DIAGNOSTIC SYSTEMS, INC. 3661 HORSEBLOCK ROAD MEDFORD, NY 11763 USA

> Tel: 1-844-снемвю (1-844-243-6246)

Email: *info@chembio.com* Web Site: *www.chembio.com*

	SYMBOL LEGEND
(in	CONSULT THE MANUAL BEFORE USE
$\langle \mathbf{I} \rangle$	WARNING
2	DO NOT RE-USE
ł	FOR USE WITHIN TEMPERATURE LIMITS
IVD	IN VITRO DIAGNOSTIC MEDICAL DEVICE
LOT	BATCH CODE
REF	PRODUCT CATALOG NUMBER
1	MANUFACTURERS IDENTIFICATION
~	DATE OF MANUFACTURE
8	USE BY DATE

